A simple ion chromatographic (IC) method was developed and validated for simultaneous or individual determination of zoledronic, alendronic, pamidronic acids and their related substances in pharmaceutical formulation. The analytes were separated on Waters IC-Pak Anion HR analytical column with a nitric acid (3 mM) without any other additives, as mobile phase at a flow rate of 1.0 mL min−1. Inverse UV detection was used at 240 nm. Important chromatographic factors that influence the chromatography responses were screened by 11/12 Pluckett–Burman design and their interaction were assayed by 23 full factorial design. The RP-HPLC method was optimized with the aid of LC-Simulator® (ACD Labs, Toronto, Ontario, Canada) software. Validated method was successfully used for quantitative analysis of PAMIFOS®, concentrate for infusion (Habitfarm AD, Ivanjica, Serbia), ZOMETA®, powder for infusion (Novartis Pharma, Stein AG, Switzerland) and BONAP® tablets (Hemofarm, Vrsac, Serbia). Total chromatographic analysis time per sample was approximately 6 min, which represents significant improvement over existing methods. Validation studies revealed that the method is specific, rapid, reliable, and reproducible. Calibration plots were linear over the concentration ranges 20–120 μg mL−1 and 0.1–2 μg mL−1 for bisphosponates and their related substances, respectively. The LODs were 8.7, 4.7, 2.5, 0.026 and 0.011 μg mL−1 for alendronate, pamidronate, zoledronate, phosphoric acid and phosphorous acid, respectively.
Irodalom 1. S Adami N Zamberlan 1996 Adverse effects of bisphosphonates: a
-Khashan HI, Mishriky AM, et al. Physicians’ awareness of bisphosphonates-related osteonecrosis of the jaw. Saudi Med J. 2011; 32: 830–835. 6 Kaposvári I
References 1 Christodoulou, C., Pervena, A., Klouvas, G., et al.: Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the
Marx RE, Sawatari Y, Fortin M, et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005; 63
–2768. Brozoski, M. A., Traina, A. A., Deboni, M. C., et al.: Bisphosphonate-related osteonecrosis of the jaw. Rev. Bras. Reumatol., 2012, 52 (2), 265–270. Ruggiero, S. L., Dodson, T. B., Fantasia, J., et al.: American
the jaw – 2014 update. J Oral Maxillofac Surg. 2014; 72; 1938–1956. 2 Baron R, Ferrari S, Russell RG. Denosumab and bisphosphonates: different mechanisms of action and
Biszfoszfonát-kezelés során fellépő állcsontnecrosis
Gyakorlati útmutató a biszfoszfonáttal kezelt betegeknél fellépő osteonecrosis megelőzéséhez és kezeléséhez
. 3. B Mehrotra S Ruggiero 2006 Bisphosphonate complications including osteonecrosis of the jaw
2008 Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel Ann Oncol 19 420 432
YC Shen 2009 Bisphosphonate zoledronic acid enhances the inhibitory effects of gefitinib on EGFR-mutated non-small cell lung carcinoma cells Cancer Lett
